Loading data for MYGN — first visit, this takes a few seconds.

Myriad Genetics, Inc.

NasdaqGS: MYGN · Real-Time Price · USD
3.42
+0.06 (1.79%)
At close: Sep 11, 2026, 3:59 PM
3.43
+0.29%
After-hours: 7:50 PM

The price, the headline numbers and the latest news, in one place.

Myriad Genetics, Inc. (MYGN) Stock Price, Analysis & Data

1.79% (1D)
Bid2.41
Market Cap327M
Revenue (ttm)557M
Net Income (ttm)-230M
1.64
-1.18
n/a
-5.97
P/B (ttm)1.08
P/S (ttm)0.59
Earnings DateNov 3, 2025
Ask4.1
Volume2,550,526
Avg. Volume (20D)1,863,882
Open3.37
Previous Close3.36
Day's Range3.19 - 3.42
52-Week Range2.74 - 8.59
Analystn/a
Price Targetn/a
Dividendsn/a
Ex-Dividend Daten/a

About MYGN

Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate...

Sector Healthcare
IPO Date Oct 6, 1995
Employees 2,700
Stock Exchange NasdaqGS
Ticker Symbol MYGN
Full Company Profile

Financial Performance

In 2025, Myriad Genetics's revenue was 824.5M, a decrease of -1.56% compared to the previous year's 837.6M. Earnings were -365.9M, an increase of 187.43%.

Financial Statements

Earnings Surprise

Myriad Genetics has released their quarterly earnings on Jul 30, 2026:
  • Revenue of n/a misses estimates by $0, with -100.00% YoY decline.
  • EPS of -0.25 misses estimates by -0.19, with -733.33% YoY decline.
Myriad Genetics, Inc. is scheduled to release its earnings on Nov 3, 2025, after market closes.
Analysts project revenue of ... Upgrade